NEXALIN TECHNOLOGY INC
NXLNASDAQTrading Snapshot
- Day Range
- $4.50 – $4.61
- 52-Week Range
- $4.00 – $60.00
- Volume
- $4.03B
- Avg Volume
- $5.12B
- Shares Outstanding
- 733,710
- Next Earnings
- Nov 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $301,647
- Last Q Revenue
- $12,161
- P/E Ratio
- -0.3
- P/S Ratio
- 14.8x
- EPS (TTM)
- $-12.75
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +102.1%
Why Investors Own NXL
- ✓High-growth profile — revenue up +14.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 65% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
NEXALIN TECHNOLOGY INC
NXL
StockOtter · stockotter.spaceAbout NEXALIN TECHNOLOGY INC
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy
Appointment as Senior Strategic Advisor marks the Company's expansion from clinical development toward commercialization of its DIFS™ platform in the United States, Europe and South America DiTota spent over two decades
LogicMark (OTCMKTS:LGMKD) vs. Nexalin Technology (NASDAQ:NXL) Head to Head Comparison
Nexalin Technology (NASDAQ: NXL - Get Free Report) and LogicMark (OTCMKTS:LGMKD - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the s
Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer's Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer's Pilot Study
Further analysis of ADAS-Cog data from the Company's randomized, sham-controlled clinical trial — previously published in the Journal of Alzheimer's Disease and in Radiology — identifies specific improvements in cognitiv
Nexalin Technology Announces Reverse Stock Split
HOUSTON, TX, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), announces that its board of directors has approved a 1-for-30 reverse stock split of the Company's commo